SINGAPORE, 14 APRIL 2022: Us2.ai, the Singapore-based medtech developers of FDA- cleared AI software that, for the first time ever, fully automates a complete echocardiography (heart ultrasound) report, today announced...
Mirati Therapeutics (formerly MethylGene) is a targeted oncology company developing a pipeline of oncology therapeutics for precisely defined patient populations. Mirati is currently advancing three drug candidates through clinical development for multiple oncology indications.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.